Allos Therapeutics to Present at the 2006 Needham & Company Biotechnology Conference
07 June 2006 - 11:00PM
PR Newswire (US)
WESTMINSTER, Colo., June 7 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that the Company
will participate in the 2006 Needham & Co. Biotechnology
Conference, to be held June 14th - 15th in New York City. Paul L.
Berns, the Company's President and Chief Executive Officer, will
give a 25-minute corporate overview on Wednesday, June 14th at 1:30
PM ET. The presentation will be webcast live and may be accessed by
visiting the Allos website at http://www.allos.com/. A replay of
the webcast will also be available on the Company's website until
Friday, June 30, 2006. About Allos Therapeutics, Inc. Allos
Therapeutics, Inc. (NASDAQ:ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. The Company's lead
product candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic
small molecule designed to sensitize hypoxic, or oxygen-deprived,
tumor tissue during radiation therapy. EFAPROXYN is currently being
evaluated as an adjunct to whole brain radiation therapy in a
pivotal Phase 3 trial in women with brain metastases originating
from breast cancer. The Company's other product candidates are: PDX
(pralatrexate), a small molecule chemotherapeutic agent (DHFR
inhibitor) currently under investigation in patients with non-small
cell lung cancer and Non-Hodgkin's lymphoma; and RH1, a small
molecule chemotherapeutic agent bioactivated by the enzyme
DT-diaphorase currently under evaluation in patients with advanced
solid tumors. For more information, please visit the Company's web
site at: http://www.allos.com/. Safe Harbor Statement The
anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties, including those
to be discussed in the presentation and others that can be found in
the "Risk Factors" section of the Company's Form 10-K for the year
ended December 31, 2005 and in the Company's periodic reports on
Form 10-Q and Form 8-K. The Company does not undertake any
obligation to update any forward-looking statements contained in
the anticipated presentation as a result of new information, future
events or otherwise. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer
Neiman, Manager, Corporate Communications of Allos Therapeutics,
+1-720-540-5227, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics (MM) News Articles